1-3 of 3
Nathalie Spielewoy
Close
Sort by
Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Clinical Trials & Observations
Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Robin Gasiorowski, Richard Greil, Árpád Illés, Nathalie A. Johnson, Jean-François Larouche, Pieternella J. Lugtenburg, Caterina Patti, Gilles A. Salles, Marek Trněný, Sven de Vos, Farheen Mir, Divya Samineni, Su Y. Kim, Yanwen Jiang, Elizabeth Punnoose, Arijit Sinha, Emma Clark, Nathalie Spielewoy, Kathryn Humphrey, Alexandra Bazeos, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 137 (5): 600–609.
https://doi.org/10.1182/blood.2020006578
Published: 2021
Includes: Supplemental data
Journal Articles

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Clinical Trials & Observations
Pier Luigi Zinzani, Ian W. Flinn, Sam L. S. Yuen, Max S. Topp, Chiara Rusconi, Isabelle Fleury, Katell Le Dû, Christopher Arthur, Barbara Pro, Giuseppe Gritti, Michael Crump, Adam Petrich, Divya Samineni, Arijit Sinha, Elizabeth A. Punnoose, Edith Szafer-Glusman, Nathalie Spielewoy, Mehrdad Mobasher, Kathryn Humphrey, Martin Kornacker, Wolfgang Hiddemann
Journal: Blood
Blood (2020) 136 (23): 2628–2637.
https://doi.org/10.1182/blood.2020005588
Published: 2020
Includes: Supplemental data
Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2917.
https://doi.org/10.1182/blood-2019-123664
Published: 2019